Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
PT Medikaloka Hermina Tbk (HEAL.JK)
IDR895.00
-5.00 (-0.56%)
ID JKT Healthcare Medical - Care Facilities
Address
Hermina Tower 10610
Jakarta, ID
Jakarta, ID
CEO
Yulisar Khiat
Website
herminahospitals.com
IPO
2018-05-17
ISIN ID1000143100
Description
PT Medikaloka Hermina Tbk oversees a comprehensive network of general hospitals spanning Indonesia. By December 31, 2021, the company's operations encompassed 43 medical facilities, collectively providing 5,877 beds. In addition to its healthcare services, the firm also participates in investment and educational service ventures. Established in 1985, its headquarters are situated in Jakarta, Indonesia.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
IDR895.00
-5.00 (-0.56%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
10M
Beta
-0.19
Float Shares
10.49B
Free Float %
68.3%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.50% | -3.38% | -18.03% | -25.09% | -29.33% | -27.54% | -23.08% | -24.53% | +10.13% | +57.73% | +57.73% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Price Targets & DCF
Current price
895.00
Ratings Trend (MoM)
92% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 3 | 0 |
| Buy | 8 | 0 |
| Hold | 1 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
3.21
Safe zone
Piotroski F-Score
5 / 9
Average
MOAT Score
4 / 10
Developing
Composite Rating
C+
Overall Score
2 / 5
Medium
DCF Score
1 / 5
Low
ROE Score
3 / 5
Medium
ROA Score
4 / 5
High
D/E Score
1 / 5
Low
P/E Score
1 / 5
Low
P/Book Score
2 / 5
Medium
Operational MOAT
✗ Below peers
-
Revenue growth Medical - Care Facilities: +10.2%+5.9% Q1'26: +5.4% (vs Q1'25)
-
EPS growth Medical - Care Facilities: +19.2%-21.0% Q1'26: -18.8% (vs Q1'25)
-
FCF margin FCF growth · Medical - Care Facilities: +32.0%+7.0% Q1'26: -0.9% (vs Q1'25)
-
EBIT margin Medical - Care Facilities: +11.3%+13.2% ★ Q1'26: +12.1% (vs Q1'25)
-
ROIC Medical - Care Facilities: +6.8%+7.1% ★ Q1'26: +6.7% (vs Q1'25)
-
Share dilution Medical - Care Facilities: +0.0%+1.9% Q1'26: +0.0% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Medical - Care Facilities: 0.99×1.77× Q1'26: 2.05× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 7 Rev. Ana. 7 EPS Ana. |
Dec 2027 10 Rev. Ana. 9 EPS Ana. |
Dec 2028 5 Rev. Ana. 3 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
3.06T
est: 3.08T (-0.6%)
|
3.63T
est: 3.61T (+0.4%)
|
4.42T
est: 3.88T (+13.7%)
|
5.82T
est: 5.82T (+0.1%)
|
4.90T
est: 4.91T (-0.1%)
|
5.78T
est: 6.44T (-10.1%)
|
6.74T
est: 6.72T (+0.3%)
|
7.13T
est: 7.11T (+0.4%)
|
7.77T
7.52T – 7.96T
+9.4% YoY
|
8.51T
7.91T – 9.51T
+9.5% YoY
|
9.11T
9.03T – 9.19T
+7.0% YoY
|
| EBITDA |
593.70B
est: 865.20B (-31.4%)
|
841.21B
est: 1.02T (-17.2%)
|
1.37T
est: 1.09T (+25.5%)
|
2.22T
est: 1.63T (+36.1%)
|
1.17T
est: 1.38T (-14.9%)
|
1.58T
est: 1.74T (-8.9%)
|
1.35T
est: 1.81T (-25.8%)
|
1.82T
est: 1.92T (-5.1%)
|
2.10T
2.03T – 2.15T
+9.4% YoY
|
2.30T
2.14T – 2.57T
+9.5% YoY
|
2.46T
2.44T – 2.48T
+7.0% YoY
|
| EBIT |
406.23B
est: 606.60B (-33.0%)
|
614.35B
est: 712.49B (-13.8%)
|
1.07T
est: 765.41B (+40.4%)
|
1.79T
est: 1.15T (+56.1%)
|
619.92B
est: 967.14B (-35.9%)
|
849.95B
est: 1.13T (-24.5%)
|
1.09T
est: 1.17T (-7.5%)
|
941.36B
est: 1.24T (-24.2%)
|
1.36T
1.31T – 1.39T
+9.4% YoY
|
1.49T
1.38T – 1.66T
+9.5% YoY
|
1.59T
1.58T – 1.61T
+7.0% YoY
|
| Net Income |
124.37B
est: 150.35B (-17.3%)
|
343.92B
est: 253.29B (+35.8%)
|
645.64B
est: 359.89B (+79.4%)
|
995.97B
est: 925.95B (+7.6%)
|
298.60B
est: 315.03B (-5.2%)
|
437.35B
est: 578.16B (-24.4%)
|
535.94B
est: 599.39B (-10.6%)
|
429.55B
est: 493.98B (-13.0%)
|
523.29B
439.88B – 574.46B
+5.9% YoY
|
635.68B
465.49B – 823.78B
+21.5% YoY
|
621.10B
582.25B – 704.83B
-2.3% YoY
|
| SGA |
168.69B
est: 121.53B (+38.8%)
|
187.92B
est: 142.75B (+31.6%)
|
258.25B
est: 153.35B (+68.4%)
|
221.36B
est: 229.65B (-3.6%)
|
229.03B
est: 193.77B (+18.2%)
|
156.10B
est: 394.33B (-60.4%)
|
183.42B
est: 411.42B (-55.4%)
|
1.19T
est: 435.30B (+174.2%)
|
476.06B
460.38B – 487.74B
+9.4% YoY
|
521.51B
484.72B – 582.72B
+9.5% YoY
|
557.96B
553.22B – 562.70B
+7.0% YoY
|
| EPS |
8.86
est: 10.13 (-12.5%)
|
23.14
est: 17.07 (+35.6%)
|
43.54
est: 24.25 (+79.6%)
|
67.73
est: 62.39 (+8.6%)
|
20.64
est: 21.23 (-2.8%)
|
30.16
est: 39.46 (-23.6%)
|
35.93
est: 39.10 (-8.1%)
|
28.40
est: 32.23 (-11.9%)
|
33.47
29.08 – 37.98
+3.9% YoY
|
39.07
30.78 – 54.47
+16.7% YoY
|
41.50
38.50 – 46.60
+6.2% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-12 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-11 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-08 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-07 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-06 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-05 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-04 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-30 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-29 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-28 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-27 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-24 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-23 | C+ | 2/5 | 1/5 | 3/5 | 5/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-22 | C+ | 2/5 | 1/5 | 3/5 | 5/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-21 | C+ | 2/5 | 1/5 | 3/5 | 5/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-20 | C+ | 2/5 | 1/5 | 3/5 | 5/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-17 | C+ | 2/5 | 1/5 | 3/5 | 5/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-16 | C+ | 2/5 | 1/5 | 3/5 | 5/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-15 | C+ | 2/5 | 1/5 | 3/5 | 5/5 | 1/5 | 1/5 | 2/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
62.34B
OE per share TTM
4.06
Owner's Yield
0.41%
Maintenance CapEx ratio
165.67%
Maint CapEx / Avg PPE
108.0%
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
Insider Activity
Insider Activity — Latest Quarter
No insider activity available.
Insider buys vs sells (history)
Insider history not available.
Recent insider transactions
No recent insider transactions.
Executive team
Top executives
EBIT / Employee
53.41M
Shares Outstanding
15.37B
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
No proxy statements available for this company yet.
Recent SEC filings
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Arie Setyo Wahyudi | Head of Licensing & Legal | — | — |
| Binsar Parasian Simorangkir | MD of Medical and Compliance & Vice President Commissioner | — | — |
| Chatarina Sri Haryanti Marsiyo | Head of Internal Audit | — | female |
| H. Hasmoro | President Director | — | — |
| Hastiyudo Wibowo | Business Development | — | — |
| Iing Ichsan Hanafi | Corporate Secretary | — | — |
| Meijani Wibowo | Commissioner | — | female |
| Muyi Ayoe Hapsari | Head of Marketing | — | — |
| Susi Setiawaty | MD of Human Capital, Corporate Secretary & Director | — | female |
| Tan Suryanti Gunadi | MD of Operational & General Affairs and Director | — | — |
| Yulisar Khiat | President Director | — | male |
| Yuyun Gunaedi | Information Technology | — | — |
ESG Score History
No data available for this company.
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for HEAL.JK
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
